These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 23262058

  • 1. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M, Imanidis G.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):554-62. PubMed ID: 23262058
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K, Grohganz H, Laitinen R, Strachan C, Rades T.
    Eur J Pharm Biopharm; 2013 Nov 14; 85(3 Pt B):873-81. PubMed ID: 23537574
    [Abstract] [Full Text] [Related]

  • 5. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y, Carr RA, Spence JK, Wang WW, Turner TM, Lipari JM, Miller JM.
    Mol Pharm; 2010 Oct 04; 7(5):1516-26. PubMed ID: 20715778
    [Abstract] [Full Text] [Related]

  • 6. Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
    Cui Y, Chiang PC, Choo EF, Boggs J, Rudolph J, Grina J, Wenglowsky S, Ran Y.
    Int J Pharm; 2013 Sep 15; 454(1):241-8. PubMed ID: 23834830
    [Abstract] [Full Text] [Related]

  • 7. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K, Laitinen R, Strachan C, Rades T, Grohganz H.
    Eur J Pharm Biopharm; 2013 Nov 15; 85(3 Pt B):882-8. PubMed ID: 23567485
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M, Nick S, Parrott N, Röthlisberger D.
    Eur J Pharm Sci; 2006 Jan 15; 27(1):91-9. PubMed ID: 16219449
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Practical Approach to Modeling the Impact of Amorphous Drug Nanoparticles on the Oral Absorption of Poorly Soluble Drugs.
    Stewart AM, Grass ME.
    Mol Pharm; 2020 Jan 06; 17(1):180-189. PubMed ID: 31743032
    [Abstract] [Full Text] [Related]

  • 17. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P, Morelli A, Pezzetta D, Rocchetti M, Poggesi I.
    Eur J Pharm Sci; 2007 Nov 06; 32(3):169-81. PubMed ID: 17714921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A.
    Mol Pharm; 2012 Jul 02; 9(7):2009-16. PubMed ID: 22632106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.